M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
The National Eye Institute's stem cell-based therapy safely prevented blindness in animal models of age-related macular degeneration.
Immuno-oncology player Five Prime is axing 20% of its workforce and its early-stage R&D in order to focus on its clinical cancer programs.
The series B round will support the startup’s efforts to build a portfolio of subsidiaries with assets targeting eight aging pathways.
The investment, which values Juvenescence at $400 million, tees the anti-aging startup to advance its multiasset pipeline.
The FDA plans to hire at least 50 reviewers for cell and gene therapies ahead of what it describes as a surge of products entering development.
While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there are becoming untenable for some.
Seres Therapeutics is promoting its chief operating and financial officer, Eric Shaff, to succeed Roger Pomerantz as its new president and CEO.
Buoyed by the improved outlook, the agency has predicted its core drug evaluation activities will be unaffected by the Brexit-enforced move.
Aimmune has confirmed that the government shutdown will delay the FDA’s review of AR101, its oral immunotherapy for peanut allergy.
Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.